Clinical trials: Residual Disease
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Primary Breast Cancer
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases.
- Trial name
- MRD-1 (NCT00172068)
- Testing
- Zoledronic acid + Calcium/Vitamin D
- Where
- 4 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to…
- Trial name
- STRENGTH (NCT02104817)
- Testing
- Epanova® (omega-3 carboxylic acids), corn oil control
- Where
- 684 sites in United States, Australia and 20 more
- Volunteers
- 13,078 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukemia
Study of GDX012 in Patients With MRD Positive AML
The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry.
- Trial name
- NCT05001451
- Testing
- GDX012 Suspension for IV Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GammaDelta Therapeutics Limited
Type 1 Diabetes Mellitus
Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes
This clinical study will evaluate the safety of an innovative approach expected to be disease-modifying by stopping the auto-immune-mediated destruction of islet β-cells in the pancreas.
- Trial name
- NCT03272269
- Testing
- IMCY-0098
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 41 people
- Sponsor
- Imcyse SA
Urolithiasis
Efficacy of Neorenal Forte for the Complete Elimination of Residual Fragments
The purpose of this study is to evaluate the efficacy of a specialized formula of phytotherapeutic extracts (Neorenal Forte) aiding the complete elimination of residual fragments after fURS in adults.
- Trial name
- NERFA (NCT06651294)
- Testing
- Neorenal Forte
- Where
- 9 sites in Bulgaria
- Volunteers
- 120 people
- Sponsor
- Neopharm Bulgaria Ltd.
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Acute Myeloid Leukemia
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in 33 adults with acute myeloid leukemia (AML) who are in morphologic complete remission with residual measurable disease and who are currently not…
- Trial name
- NCT04632316
- Testing
- Cyclophosphamide-Fludarabine (Cy/Flu), oNKord®
- Where
- 10 sites in Belgium, France and 3 more
- Volunteers
- 33 people
- Sponsor
- Glycostem Therapeutics BV
Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD.
- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
- Trial name
- NCT06754852
- Testing
- HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 108 people
- Sponsor
- Hemab ApS
B-precursor Acute Lymphoblastic Leukemia
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT04506086
- Testing
- Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS)
- Where
- 12 sites in United States
- Volunteers
- 10 people
- Sponsor
- Amgen
Ureteral Calculi
Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy
Objective: To observe the effect of Ningmitai capsule on ureteral calculi after lithotripsy and evaluate the safety of treatment.
- Trial name
- 3 (NCT06105827)
- Testing
- Control group, Ningmitai capsule, Combined group (Ningmitai plus tamsulosin)
- Volunteers
- 251 people
- Sponsor
- Xintian Pharmaceutical
Pancreatic Cancer
Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
This is a multicenter, prospective, observational study to evaluate the utility of the Invitae Personalized Cancer MonitoringTM assay for patients with resectable and unresectable pancreatic cancer.
- Trial name
- ARTEMIS-PC (NCT06043921)
- Testing
- No intervention
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Invitae Corporation
Prostate Cancer, Neoplasm, Residual
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
The primary objective of this feasibility study is to determine if administration of LUM015 will result in positive fluorescence of tumor tissue from ex vivo specimen imaging with the LUM Imaging device from patients undergoing…
- Trial name
- NCT03441464
- Testing
- LUM Imaging System
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Lumicell, Inc.
Leukemia, Myeloid, Acute
HDM201 Added to CT in R/R or Newly Diagnosed AML
This is a multi-center open-label Phase I/II study investigating orally administered HDM201 in combination with chemotherapy in two populations: subjects with first line AML or subjects with relapsed/refractory AML.
- Trial name
- NCT03760445
- Testing
- HDM201, cytarabine, anthracycline
- Sponsor
- Novartis Pharmaceuticals
Colonic Neoplasms, Colorectal Neoplasms
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
The primary objective is to assess and characterize the antitumor activity and safety and tolerability of adjuvant treatment with an individualized neoantigen vaccine called GRT-C901/GRT-R902 (chimpanzee adenovirus [ChAd] and…
- Trial name
- NCT05456165
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 3 sites in United States
- Sponsor
- Gritstone bio, Inc.
Ovarian Cancer
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of…
- Trial name
- NCT03614689
- Where
- 6 sites in China
- Volunteers
- 104 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Type I Hypersensitivity
Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of the modified ragweed pollen in Ragweed MATA MPL (modified pollen allergen tyrosine adsorbate + Monophosphoryl Lipid A) by skin prick testing.
- Trial name
- NCT00116285
- Testing
- Ragweed MATA MPL
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Allergy Therapeutics
Carcinoma, Non- Small Cell Lung
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
- Trial name
- MERMAID-2 (NCT04642469)
- Testing
- Durvalumab
- Where
- 115 sites in United States, Argentina and 23 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Multiple Myeloma
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance…
- Trial name
- AURIGA (NCT03901963)
- Testing
- Daratumumab, Lenalidomide
- Where
- 73 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC